San Diego, California, United States – September 17, 2026 – A new publishing release, Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences by Dr. David H. Crean, is here to provide a blueprint for biopharma companies struggling to navigate the treacherous space between early discovery and commercialization.

Highlighting industry metrics showing that roughly half of approved therapeutics fail to recover their development costs, Dual Fluency explores the root organizational causes behind biopharma asset attrition. The book establishes a structured framework centered on three core translations required for life sciences success:

Core Frameworks Featured in ‘Dual Fluency’:

• Data to Capital: Methods for converting raw preclinical assays, biomarker readouts, and biological data into probability-weighted valuation models that institutional investors underwrite.
• Discovery to Deal: Strategies for structuring licensing agreements, strategic partnerships, and non-dilutive financing mechanisms that align with clinical realities.
• Bench to Boardroom: Operational models for board governance, helping executives transition from research exploration to capital prioritization and disciplined asset management.
• Capital Stack Optimization: Guidance on leveraging non-dilutive BARDA grants, royalty monetization, venture debt, and crossover investment to avoid unnecessary equity surrender.

Designed for scientist-founders, pre-commercial CEOs, business development executives, and healthcare investors, Dual Fluency offers actionable insights to reduce risk at every stage of development.

Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences will soon be avaibale on Amazon and leading bookstores.

About the Author:

David H. Crean, PhD, MBA, is Founder and Managing Partner of Cardiff Advisory LLC, a boutique life sciences M&A and strategic advisory firm based in San Diego, CA. Over three decades, he has closed more than fifty transactions spanning M&A, licensing, partnering, and capital raises across numerous therapeutic area disciplines.

A former senior executive at Allergan, he also serves as Fractional Chief Business Officer of MediciNova, Inc. (NASDAQ: MNOV), co-founded CEO360, and holds FINRA Series 79 and 63 registrations.

Dr. Crean has advised and mentored more than 250 life sciences CEOs, boards of directors, and entrepreneurs over the past five years on issues of growth and exit. He has been named five consecutive times to the San Diego Business Journal SD500 Most Influential list.

Book Name: Dual Fluency: The Language of Science and Capital in Life Sciences

Author Name: David H. Crean

ISBN Number: 979-8952851153

Kindle Version: Click Here

Paperback Version: Click Here

Media Contact
Company Name: American Publishers Inc
Contact Person: Media Relations
Email: Send Email
Phone: +1(818)483-1118
Address:12100 Wilshire Boulevard, 8th Floor
City: Los Angeles
State: CA 90025
Country: United States
Website: https://americanpublishersinc.com/